EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease

Ramiro Eduardo Rea Reyes iD, Karly A Cody, Rachael E Wilson, Henrik Zetterberg, Nathaniel A Chin, Erin M Jonaitis, Melissa Bahr, Olivia Mandel, Madilynn Wintlend, Barbara B Bendlin, Ozioma C Okonkwo, Lindsay R Clark und 7 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Ramiro Eduardo Rea Reyes und 18 weiteren Autor:innen. Beteiligte Einrichtung: Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: tau Proteins, Positron-Emission Tomography, Alzheimer Disease, Temporal Lobe. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Alzheimer's Association Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Patterns of signal from tau positron emission tomography (tau‐PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer's disease (AD) research if they are linked to differential biomarker levels and cognitive decline. METHODS Visual assessment of Tau‐PET [F‐18]florquinitau (FQT) exams from 728 initially non‐demented older adults yielded four uptake groups: tau‐negative (T−), MTL‐only (T+ MTL ), neocortex‐only (T+ Neo ), or both (T+ MTL&Neo ). Mixed effects models assessed group differences in retrospective cognitive and plasma pTau217 trajectories. RESULTS T+ MTL&Neo was the most common T+ group ( n = 97; 93% A+) and exhibited the sharpest worsening in cognitive and pTau217 trajectories before tau PET. DISCUSSION The T+ MTL&Neo category represents an intermediate to advanced stage of AD preceded by rising ptau217 and progressive cognitive decline. The pTau217 finding suggests that A+, T+ in MTL or neocortex could represent early AD stages, with a higher likelihood of progressing to more advanced stages. Highlights Visual assessments of Tau‐PET FQT revealed four distinct uptake groups: tau‐negative (T−), MTL‐only (T+ MTL ), neocortex‐only (T+ Neo ), or both (T+ MTL&Neo ). Amyloid positive participants in the T+ MTL and T+ MTL&Neo categories showed a retrospectively faster decline in their cognitive trajectories, and a sharper increase in pTau217 levels in plasma, compared to T−. The T+ MTL&Neo group displayed sharper trajectories compared with the other Tau positive groups in both their cognitive scores and pTau217 plasma levels. Our results suggest that participants with Tau present in both MTL and neocortex represent an intermediate to advanced stage of AD, whereas participants with signals confined to either MTL or neocortex could represent earlier AD stages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsPositron-Emission TomographyAlzheimer DiseaseTemporal LobeCognitive DysfunctionHumansMaleFemaleAgedNeocortexAged, 80 and overRetrospective StudiesBiomarkersCohort StudiesCarbolines

Stichwörter der Autor:innen

PET qualitative assessmentPET visual readcognitive compositecognitive trajectoriespTau217plasma biomarkers

Substanzen

tau ProteinsBiomarkersCarbolines

Autor:innen und Institutionen

  • Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
  • UK Dementia Research Institute at UCL, London, UK.

ORCID-Profile: Ramiro Eduardo Rea Reyes, Sterling C Johnson

Förderung

  • NIH HHS
  • NIA NIH HHS
  • Alzheimer's Association Research Foundation
  • Wisconsin Alzheimer's Disease Research Center
  • National Institutes of Health

Zitieren

APA

Rea Reyes, R. E., Cody, K. A., Wilson, R. E., Zetterberg, H., Chin, N. A., Jonaitis, E. M., Bahr, M., Mandel, O., Wintlend, M., Bendlin, B. B., Okonkwo, O. C., Clark, L. R., Zammit, M., Asthana, S., Christian, B. T., Betthauser, T. J., Eisenmenger, L., Langhough, R. E., & Johnson, S. C. (2025). Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14406

Vancouver

Rea Reyes RE, Cody KA, Wilson RE, Zetterberg H, Chin NA, Jonaitis EM, et al. Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14406

BibTeX
@article{ReaReyes2025,
  author = {Rea Reyes, Ramiro Eduardo and Cody, Karly A and Wilson, Rachael E and Zetterberg, Henrik and Chin, Nathaniel A and Jonaitis, Erin M and Bahr, Melissa and Mandel, Olivia and Wintlend, Madilynn and Bendlin, Barbara B and Okonkwo, Ozioma C and Clark, Lindsay R and Zammit, Matt and Asthana, Sanjay and Christian, Bradley T and Betthauser, Tobey J and Eisenmenger, Laura and Langhough, Rebecca E and Johnson, Sterling C},
  title = {Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14406}
}
Kostenlos starten →